FDA ap­proves Ipsen’s Onivyde as first-line treat­ment for type of pan­cre­at­ic can­cer

The FDA on Tues­day ap­proved Ipsen’s can­cer drug Onivyde as the first-line treat­ment for a type of pan­cre­at­ic can­cer, to be used along­side oth­er can­cer med­ica­tions.

The ap­proval of Onivyde (irinote­can li­po­some) is based on pos­i­tive re­sults from the com­pa­ny’s NAPOLI 3 tri­al, which eval­u­at­ed 770 pa­tients with metasta­t­ic pan­cre­at­ic ade­no­car­ci­no­ma who had not pre­vi­ous­ly re­ceived chemother­a­py for their metasta­t­ic dis­ease. The tri­al showed that Onivyde ex­tend­ed pa­tients’ lives two months longer than the cur­rent stan­dard of care.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.